Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2000

View Archived Issues

Northwest's prostate cancer vaccine shows favorable progress in clinical trial

Endo meets with FDA to clarify requirements for MorphiDex approval

FDA completes review of supplemental BLA for Rituxan

Salus receives NIH grant to aid in development of anti-HIV treatment

Angiogenic activity suggests broadened role for statins

Hollis-Eden cleared to commence further HIV clinical trials in South Africa

Interferon beta delays development of multiple sclerosis in high-risk subjects

SBIR grant awarded to Imgenex to develop monoclonal antibodies for osteoporosis

Newly synthesized selective AMPA agonist used to elucidate receptor function

Acidic quinolones with potent antibacterial activity identified at Wakunaga

Servier investigates synergistic interaction between alpha2 blockade and monoamine uptake inhibition

Sigma-Tau selects new camptothecin derivative for preclinical development

Potent adenosine transporter inhibitors synthesized by Kyowa Hakko useful as tools and leads

FDA approves Mifeprex for termination of early pregnancy

New approach to oncolytic, skin disorders based on specific inhibition of 4-hydroxylase

First oral drug for rare neurodegenerative disease launched in Japan

Selective COX-2 inhibitor with promising profile emerges from Abbott R&D

Efficacy in experimental IBD demonstrated for immunosteroid recently acquired by Hollis-Eden

Two new patents cover VCAM-1/VLA-4 inhibitors from Roche and their use

Beacon describes preparation and activity of improved butyric acid esters

Meiosis-regulating cholestane compounds designed by Schering

Newly isolated antibiotic characterized at Pola as having antifungal and antibacterial activity

Chugai examines novel enzyme inhibitors as potential anticancer agents

Migration-inhibitory peptides identified and investigated at Kyowa Hakko

New vitamin D compounds for bone disorders prepared at Sumitomo

Taiho describes new series for use in reducing elevated ammonia levels

Bosentan begins FDA approval process for pulmonary hypertension

Ligand's lasofoxifene enters phase III for osteoporosis, triggering milestone payment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...